For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
“Indian Peptides and Heparin Market projected to grow at a CAGR of 15.0% and 4.9% respectively”
The Indian peptides market is expected to reach USD 883.0 million in 2022 from USD 381.8 million in 2016 and is expected to register a CAGR of 15.0%, and the Indian heparin market is projected to reach USD 170.2 million by 2022, at a CAGR of 4.9%. Factors such as increasing prevalence of chronic diseases, increasing incidence of coagulation disorder, and favorable government policies are the major driving factors for the Indian peptides and heparin market. On the other hand, the availability of alternative drugs is the major restraining factor for the Indian peptides market. The patent expiry of blockbuster drugs will provide growth opportunities to players in the Indian peptides market. For example, Victorza is the brand name of the liraglutide peptide developed by Novo Nordisk. Its patent will expire in August 2017, which will enable drug manufacturers to introduce their generic versions of it.
“Bivalirud in type is expected to register the highest growth during the forecast period”
The Indian peptides market is classified on the basis of type into insulin, teriparatide, liraglutide, glucagon, leuprolide acetate, octreotide acetate, calcitonin salmon, triptorelin, eptifibatide, glatiramer acetate, bivalirudin, exenatide, and other molecules. The bivalirudin segment is expected to register the highest CAGR during the forecast period. This growth can be attributed to the increasing number of percutaneous coronary intervention procedures (PCI) in India.
“Awareness about early diagnosis drives growth of the diabetes segment”
By application, the Indian peptides market is segmented into diabetes, infectious disease, cancer, cardiology, osteoporosis, gynecological applications, and other applications. The diabetes segment is expected to register highest CAGR during the forecast period. The growth in this segment can be primarily attributed to increasing awareness of early diagnosis, increasing prevalence & incidence of diabetes, and increasing aging population.
Key players operating in the Indian peptides market include Abbott Laboratories (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India).
“Enoxaparin sodium type is expected to register the highest growth during the forecast period”
The Indian heparin market is classifiedon the basis of type into enoxaparin sodium, heparin sodium, fondaparinux, and dalteparin sodium. The enoxaparin sodium type segment is expected to register the highest growth during the forecast period. This growth can be attributed to the increasing coagulation disorders in the country.
Key players operating in the Indian heparin market include Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (U.S.), Abbott Laboratories (U.S.), Lupin Ltd. (India),Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Life sciences (India).
The primary interviews conducted for this report can be categorized as follows:
- By Company Type - Tier 1 – 70 %, Tier 2 – 30%
- By Designation – C level – 62%, Director level – 21%, Others – 17%
Research Coverage:
The report analyses the Indian peptides market by type and application and the Indian heparin market by type. Apart from comprehensive product analysis and market sizing, the report also provides the complete list of peptide and heparin manufacturers and marketing players in India. In addition, the report profiles companies with product portfolios and key financial data by key players to maintain and increase their shares in the market. The above mentioned market research data, market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.
Benefits of Buying this Report:
This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.
The report provides insights on the following strategies:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the Indian peptides and heparin market. The report analyses the Indian peptides market by type and application and the Indian heparin market by type.
- Competitive Assessment: In-depth assessment of the market strategies, business segments, and product portfolios of the leading players in the Indian peptides and heparin market.